Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azeliragon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Azeliragon overview

Azeliragon is under development for the treatment of hospitalized patients with severe COVID-19, chronic obstructive pulmonary disease (COPD) and steroid refractory asthma, metastatic pancreatic cancer, glioblastoma multiforme, triple negative breast cancer, brain metastasis and breast cancers. The drug candidate is administered through oral route and acts by targeting RAGE (receptor for advanced glycation endproducts). The drug is developed based on the TTP translational technology. It was under development for the treatment of Alzheimer’s disease (dementia with diabetes) and diabetic nephropathy.

Cantex Pharmaceuticals overview

Cantex Pharmaceuticals, formerly ParinGenix is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combination of disulfiram and copper that is in Phase II clinical trial for the treatment of recurrent glioblastoma; and completed Phase 1 trial in metastatic prostate cancer and breast cancer. Cantex Pharmaceuticals also develops CX-01 a polysaccharide used for the treatment of acute myeloid leukemia (AML), traumatic brain injury and other blood disorders. The company offers its products across the US. Cantex Pharmaceuticals is headquartered in Weston, Florida, the US

For a complete picture of Azeliragon’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.